Literature DB >> 8589145

Household contact study of Bordetella pertussis infections.

J L Deen1, C A Mink, J D Cherry, P D Christenson, E F Pineda, K Lewis, D A Blumberg, L A Ross.   

Abstract

Household contacts of primary pertussis cases were evaluated. Infection was determined by culture, direct fluorescent antibody assay, and serological criteria. Agglutinin titers and values of ELISA IgG and IgA antibodies to lymphocytosis-promoting factor, filamentous hemagglutinin, and pertactin were determined. In 39 households 255 subjects were exposed; 114 remained well (group 1), 53 had mild illness (group 2), and 88 had pertussis (group 3). The infection rates were 46% (group 1), 43% (group 2), and 80% (group 3). In a subgroup of subjects seen within 14-28 days of exposure, it was found that none with clinical pertussis had a value of IgG antibody to pertactin in acute-phase sera of > or = 50 ELISA units (EU) per mL or an agglutinin titer of > 256. Of the primary cases, 53% were > or = 13 years of age. These data point out the importance of Bordetella pertussis infections in adolescents and adults as a source of infection in young children. Our subgroup data suggest that high values of antibody to pertactin and high agglutinin titers may be predictive of protection against clinical pertussis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589145     DOI: 10.1093/clinids/21.5.1211

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Immunoglobulin A-mediated protection against Bordetella pertussis infection.

Authors:  S M Hellwig; A B van Spriel; J F Schellekens; F R Mooi; J G van de Winkel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Bordetella pertussis transmission.

Authors:  Elizabeth A Trainor; Tracy L Nicholson; Tod J Merkel
Journal:  Pathog Dis       Date:  2015-09-14       Impact factor: 3.166

4.  Imperfect vaccine-induced immunity and whooping cough transmission to infants.

Authors:  Jennie Lavine; Hélène Broutin; Eric T Harvill; Ottar N Bjørnstad
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

5.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.

Authors:  Girish S Kirimanjeswara; Luis M Agosto; Mary J Kennett; Ottar N Bjornstad; Eric T Harvill
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

6.  Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.

Authors:  Claudius U Meyer; Fred Zepp; Michael Decker; Martin Lee; Swei-Ju Chang; Joel Ward; Sandra Yoder; Hugues Bogaert; Kathryn M Edwards
Journal:  Clin Vaccine Immunol       Date:  2007-01-31

7.  Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.

Authors:  Natasha B Halasa; Alice O'Shea; Jian R Shi; Bonnie J LaFleur; Kathryn M Edwards
Journal:  J Pediatr       Date:  2008-04-28       Impact factor: 4.406

Review 8.  An overview of the status of acellular pertussis vaccines in practice.

Authors:  A L Lopez; D A Blumberg
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

9.  Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.

Authors:  Olajumoke O Fadugba; Li Wang; Qingxia Chen; Natasha B Halasa
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

10.  Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Authors:  Laurent Coudeville; Annelies Van Rie; Denis Getsios; J Jaime Caro; Pascal Crépey; Van Hung Nguyen
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.